| Dosage regime |
2022-10-05 |
2023-4-06 |
|
| Dosage regimes |
2022-7-15 |
2023-2-09 |
|
| Combination therapy using antibody-drug conjugates |
2022-6-27 |
2023-1-05 |
|
| Pyrrolobenzodiazepine-antibody conjugates |
2022-6-03 |
2023-2-23 |
|
| Combination therapy |
2022-5-16 |
2022-12-01 |
|
| Pyrrolobenzodiazepine phototherapy |
2022-5-12 |
2022-6-29 |
|
| Site-specific antibody-drug conjugates |
2022-3-01 |
2022-6-14 |
|
| Combination therapy comprising an anti-cd19 antibody drug conjugate and a pi3k … |
2021-12-06 |
2022-2-01 |
|
| Combination therapy comprising an anti-cd25 antibody drug conjugate and a … |
2021-12-06 |
2022-2-01 |
|
| Pyrrolobenzodiazepine-antibody conjugates |
2021-12-05 |
2022-2-01 |
|
| Glycoconjugates |
2021-10-14 |
2022-4-21 |
|
| Combination therapy |
2021-10-06 |
2022-4-14 |
|
| Pyrrolobenzodiazepine-antibody conjugates |
2021-9-24 |
2022-1-13 |
|
| Pyrrolobenzodiazepine-antibody conjugates and uses thereof |
2021-9-22 |
2022-3-31 |
|
| Combination therapy comprising anti-kaag1 antibody drug conjugate and parp … |
2021-8-05 |
2022-2-10 |
|
| ANTI-IL13Rα2 ANTIBODIES |
2021-7-30 |
2022-2-03 |
|
| Combination therapy |
2021-6-29 |
2021-8-11 |
|
| Combination therapy |
2021-6-29 |
2021-8-11 |
|
| Combination therapy |
2021-6-29 |
2021-8-11 |
|
| Combination therapy |
2021-5-28 |
2021-7-14 |
|
| Combination therapy |
2021-5-28 |
2021-7-14 |
|
| Combination therapy |
2021-5-28 |
2021-7-14 |
|
| Pyrrolobenzodiazepine phototherapy |
2021-5-13 |
2021-6-30 |
|
| Pyrrolobenzodiazepine-antibody conjugates |
2021-4-28 |
2021-8-26 |
|
| Combination therapy |
2021-2-23 |
2021-11-29 |
|
| Molecular adjuvant |
2021-2-19 |
2021-4-07 |
|
| Combination therapy |
2021-1-06 |
2021-9-20 |
|
| Molecular adjuvant |
2020-11-19 |
2021-6-28 |
|
| Combination therapy |
2020-11-06 |
2023-3-30 |
|
| Compounds |
2020-9-10 |
2020-10-28 |
|
| Pyrrolobenzodiazepine-antibody conjugates |
2020-8-19 |
2020-12-31 |
|
| Pyrrolobenzodiazepine-anti-psma antibody conjugates |
2020-8-06 |
2021-5-13 |
|
| Pyrrolobenzodiazepine-antibody conjugates |
2020-7-21 |
2020-11-05 |
|
| Anti-mesothelin antibodies |
2020-7-13 |
2020-8-26 |
|
| Pyrrolobenzodiazepine-anti-cd22 antibody conjugates |
2020-5-26 |
2020-10-01 |
|
| Pyrrolobenzodiazepine phototherapy |
2020-5-13 |
2020-6-24 |
|
| Pyrrolobenzodiazepine-antibody conjugates |
2020-3-02 |
2020-12-31 |
|
| Antibodies against kidney associated antigen 1 and antigen-binding fragments … |
2020-1-17 |
2020-5-21 |
|
| Pyrrolobenzodiazepine resistance |
2019-12-18 |
2021-10-27 |
|
| Dosage regime |
2019-11-25 |
2020-8-13 |
|
| Compounds |
2019-9-06 |
2019-10-23 |
|
| Combination Therapy |
2019-6-10 |
2019-7-24 |
|
| Combination therapy |
2019-6-10 |
2019-7-24 |
|
| Combination therapy |
2019-6-10 |
2019-7-24 |
|
| Combination therapy |
2019-6-10 |
2019-7-24 |
|
| Combination therapy |
2019-6-10 |
2019-7-24 |
|
| Combination therapy |
2019-6-10 |
2019-7-24 |
|
| Agents for treating triple negative breast cancer |
2019-5-22 |
2019-7-26 |
|
| Pyrrolobenzodiazepine phototherapy |
2019-5-17 |
2019-7-03 |
|
| Pyrrolobenzodiazepine resistance |
2019-3-28 |
2019-5-15 |
|
| Treatment of car t-cell toxicity |
2019-2-08 |
2022-6-09 |
|
| Pyrrolobenzodiazepine resistance |
2018-12-19 |
2019-1-30 |
|
| Combination therapy with an anti-axl antibody-drug conjugate |
2018-11-21 |
2019-7-18 |
|
| Molecular adjuvant |
2018-11-07 |
2018-12-19 |
|
| PYROLOVENZODIAZEPINE-ANTIBODY CONJECTIONS AGAINST PSMA |
2018-10-23 |
2019-12-11 |
|
| Compounds |
2018-9-05 |
2018-10-17 |
|
| Combination Therapy |
2018-8-31 |
2018-10-17 |
|
| Molecular adjuvant |
2018-8-10 |
2018-9-26 |
|
| Pyrrolobenzodiazepine-antibody conjugates |
2018-7-11 |
2018-8-29 |
|
| Pyrroloobenzodiazepine-antibody conjugates |
2018-7-11 |
2018-8-29 |
|
| Dosage Regime |
2018-5-23 |
2018-7-11 |
|
| Dosage regime |
2018-5-23 |
2018-7-11 |
|
| Combination Therapy with Anti-CD25 Antibody-Drug Conjugates |
2018-4-20 |
2019-12-11 |
|
| Combination therapy |
2018-4-20 |
2020-12-31 |
|
| Combination therapy with an anti-psma antibody-drug conjugate |
2018-4-20 |
2020-4-30 |
|
| Combination Therapy |
2018-4-05 |
2018-5-23 |
|
| Combination therapy |
2018-3-29 |
2018-5-16 |
|
| Dosage regime |
2018-2-28 |
2018-4-11 |
|
| Combination therapy |
2018-2-23 |
2018-4-11 |
|
| Dosage regime |
2018-2-20 |
2018-4-04 |
|
| Pyrrolobenzodiazepine-antibody conjugates |
2018-2-08 |
2022-3-17 |
|
| Pyrrolobenzodiazepine-antibody conjugates |
2018-2-08 |
2023-3-28 |
2023-3-28 |
| Polynucleotides and polypeptide sequences involved in cancer |
2018-1-05 |
2018-12-06 |
|
| Dosage regime |
2017-12-08 |
2018-1-24 |
|
| Dosage regime |
2017-12-08 |
2018-1-24 |
|
| Dosage regime |
2017-12-08 |
2018-1-24 |
|
| Dosage regime |
2017-12-08 |
2018-1-24 |
|
| Antibodies that specifically block the biological activity of a tumor antigen |
2017-12-06 |
2018-12-27 |
|
| Pyrrolobenzodiazepine-antibody conjugates |
2017-11-22 |
2018-1-03 |
|
| Pyrrolobenzodiazepine-antibody conjugates |
2017-11-22 |
2018-1-03 |
|
| Pyrrolobenzodiazepine-antibody conjugates |
2017-11-22 |
2018-1-03 |
|
| Pyrrolobenzodiazepines Zhuo conjugate |
2017-10-13 |
2019-6-04 |
|
| PYRROLOVENZODIAZEPIN-ANTI-ANTIBODIES ANTIBODIES |
2017-9-05 |
2018-2-14 |
|
| Dosage regime |
2017-6-30 |
2017-8-16 |
|
| Dosage regime |
2017-6-30 |
2017-8-16 |
|
| Dosage regime |
2017-6-30 |
2017-8-16 |
|
| Dosage regime |
2017-6-30 |
2017-8-16 |
|
| Dosage regime |
2017-6-14 |
2017-7-26 |
|
| Dosage regime |
2017-6-14 |
2017-7-26 |
|
| Dosage regime |
2017-6-14 |
2017-7-26 |
|
| Dosage regime |
2017-6-14 |
2017-7-26 |
|
| For the antibody and application thereof of alpha-synapse nucleoprotein |
2017-6-01 |
2019-3-15 |
|
| pyrrolobenzodiazepine-peptide conjugates |
2017-4-24 |
2017-6-07 |
|
| Combination therapy |
2017-4-20 |
2017-6-07 |
|
| Combination therapy |
2017-4-20 |
2017-6-07 |
|
| Combination therapy |
2017-4-20 |
2017-6-07 |
|
| Combination therapy |
2017-4-20 |
2017-6-07 |
|
| Combination therapy |
2017-4-20 |
2017-6-07 |
|
| Combination therapy |
2017-4-20 |
2017-6-07 |
|
| Combination therapy |
2017-4-20 |
2017-6-07 |
|